[go: up one dir, main page]

BR0311714A - Combinações que compreendem epotilonas e seus usos farmacêuticos - Google Patents

Combinações que compreendem epotilonas e seus usos farmacêuticos

Info

Publication number
BR0311714A
BR0311714A BR0311714-6A BR0311714A BR0311714A BR 0311714 A BR0311714 A BR 0311714A BR 0311714 A BR0311714 A BR 0311714A BR 0311714 A BR0311714 A BR 0311714A
Authority
BR
Brazil
Prior art keywords
inhibitors
combination
treatment
topoisomerase
simultaneous
Prior art date
Application number
BR0311714-6A
Other languages
English (en)
Inventor
John Arthur Hohneker
Julie Ann Miller
John David Rothermel
Markus Wartmann
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BR0311714A publication Critical patent/BR0311714A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3015—Breast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"COMBINAçõES QUE COMPREENDEM EPOTILONAS E SEUS USOS FARMACêUTICOS". A presente invenção refere-se a uma combinação farmacêutica que compreende (a) um anticorpo de HER-1 ou HER-2, ou (b) pelo menos um agente antineoplásico selecionado no grupo que consiste em inibidores de aromatase antiestrogênios, inibidores de topoisomerase I, inibidores de topoisomerase II, agentes ativos em microtúbulos, inibidores de proteína cinase C, compostos antiangiogênicos, agonistas de gonadorrelina, antiandrogênios, inibidores de histona desacetilase e inibidores de S-adenosilmetionina descarboxilase; e (c) um derivado de epotilona da fórmula I, e opcionalmente pelo menos um veículo farmaceuticamente aceitável, para uso simultâneo, separado ou seq³encial, particularmente para o tratamento de uma doença proliferativa, especialmente uma doença de tumor sólido; uma composição farmacêutica que compreende tal combinação; o uso de tal combinação para a preparação de um medicamento para o tratamento de uma doença proliferativa; uma embalagem ou produto comercial que compreende tal combinação como uma preparação combinada para uso simultâneo, separado ou seq³encial e um método para tratar um animal de sangue quente, especialmente um ser humano.
BR0311714-6A 2002-06-10 2003-06-06 Combinações que compreendem epotilonas e seus usos farmacêuticos BR0311714A (pt)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US38702502P 2002-06-10 2002-06-10
US40623802P 2002-08-27 2002-08-27
US40623902P 2002-08-27 2002-08-27
US43867703P 2003-01-08 2003-01-08
US43867603P 2003-01-08 2003-01-08
PCT/EP2003/005988 WO2003103712A1 (en) 2002-06-01 2003-06-06 Combinations comprising epothilones and pharmaceutical uses thereof

Publications (1)

Publication Number Publication Date
BR0311714A true BR0311714A (pt) 2005-03-01

Family

ID=29741146

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0311714-6A BR0311714A (pt) 2002-06-10 2003-06-06 Combinações que compreendem epotilonas e seus usos farmacêuticos

Country Status (16)

Country Link
US (2) US20050271669A1 (pt)
EP (2) EP1515750B1 (pt)
JP (1) JP2005535608A (pt)
CN (2) CN101816792A (pt)
AT (1) ATE476995T1 (pt)
AU (1) AU2003242646A1 (pt)
BR (1) BR0311714A (pt)
CA (1) CA2487147A1 (pt)
DE (1) DE60333754D1 (pt)
IL (1) IL165180A0 (pt)
MX (1) MXPA04012444A (pt)
NO (1) NO20050096L (pt)
PL (1) PL372070A1 (pt)
SG (1) SG162616A1 (pt)
WO (1) WO2003103712A1 (pt)
ZA (1) ZA200409137B (pt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7154002B1 (en) 2002-10-08 2006-12-26 Takeda San Diego, Inc. Histone deacetylase inhibitors
US7169801B2 (en) 2003-03-17 2007-01-30 Takeda San Diego, Inc. Histone deacetylase inhibitors
JO2596B1 (en) * 2004-11-30 2011-02-27 نوفارتيس ايه جي Compositions include epothelones and tyrosine protein kinase inhibitors and their pharmaceutical uses
US20060121511A1 (en) 2004-11-30 2006-06-08 Hyerim Lee Biomarkers and methods for determining sensitivity to microtubule-stabilizing agents
WO2006066133A2 (en) 2004-12-16 2006-06-22 Takeda San Diego, Inc. Histone deacetylase inhibitors
US7642253B2 (en) 2005-05-11 2010-01-05 Takeda San Diego, Inc. Histone deacetylase inhibitors
WO2007011626A2 (en) 2005-07-14 2007-01-25 Takeda San Diego, Inc. Histone deacetylase inhibitors
EP2099443A4 (en) * 2006-11-10 2010-05-05 Syndax Pharmaceuticals Inc ASSOCIATION OF ERA + LIGANDS AND HISTONE DEACETYLASE INHIBITORS IN THE TREATMENT OF CANCER
US20100267779A1 (en) * 2007-07-23 2010-10-21 Syndax Pharmaceuticals, Inc. Novel Compounds and Methods of Using Them
US20100298270A1 (en) * 2007-07-23 2010-11-25 Syndax Pharmaceuticals, Inc. Novel Compounds and Methods of Using Them
WO2009058895A1 (en) * 2007-10-30 2009-05-07 Syndax Pharmaceuticals, Inc. Administration of an inhibitor of hdac and an mtor inhibitor
WO2009067453A1 (en) * 2007-11-19 2009-05-28 Syndax Pharmaceuticals, Inc. Combinations of hdac inhibitors and proteasome inhibitors
WO2009126662A1 (en) * 2008-04-08 2009-10-15 Syndax Pharmaceuticals, Inc. Administration of an inhibitor of hdac, an inhibitor of her-2, and a selective estrogen receptor modulator
EP2571525A4 (en) 2010-05-18 2016-04-27 Cerulean Pharma Inc Compositions and methods for treating autoimmune and other diseases
JP7542947B2 (ja) * 2016-10-28 2024-09-02 アセチロン ファーマシューティカルズ インコーポレイテッド ヒストン脱アセチル化酵素阻害剤及びエポチロンを含む医薬品組み合わせならびにその使用方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989006692A1 (en) * 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
US5516775A (en) * 1992-08-31 1996-05-14 Ciba-Geigy Corporation Further use of pyrimidine derivatives
CA2273083C (en) * 1996-12-03 2012-09-18 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
AU753519B2 (en) * 1998-02-05 2002-10-17 Novartis Ag Compositions containing organic compounds
CA2322157C (en) * 1998-02-25 2012-05-29 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
AU5036999A (en) * 1998-06-30 2000-01-17 Schering Aktiengesellschaft Epothilon derivatives, their preparation process, intermediate products and their pharmaceutical use
AU4101800A (en) * 1999-02-11 2000-08-29 Schering Aktiengesellschaft Epothilon derivatives, method for the production and the use thereof as pharmaceuticals
DE19908760A1 (de) * 1999-02-18 2000-08-24 Schering Ag Neue Epothilon-Derivate, Verfahren zu deren Herstellung und ihre pharmazeutische Verwendung
US20020058286A1 (en) * 1999-02-24 2002-05-16 Danishefsky Samuel J. Synthesis of epothilones, intermediates thereto and analogues thereof
AU2001243372A1 (en) * 2000-03-01 2001-09-12 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
TWI310684B (en) * 2000-03-27 2009-06-11 Bristol Myers Squibb Co Synergistic pharmaceutical kits for treating cancer
DE10020517A1 (de) * 2000-04-19 2001-10-25 Schering Ag Neue Epothilon-Derivate, Verfahren zu deren Herstellung und ihre pharmazeutische Verwendung
DE10020899A1 (de) * 2000-04-20 2001-10-25 Schering Ag 9-Oxa-Epothilon-Derivate, Verfahren zu deren Herstellung sowie ihre Verwendung in pharmazeutischen Präparaten
PE20020354A1 (es) * 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
IL157443A0 (en) * 2001-03-14 2004-03-28 Bristol Myers Squibb Co Pharmaceutical compositions for the treatment of cancer including an epothilone analog and a chemotherapeutic agent

Also Published As

Publication number Publication date
MXPA04012444A (es) 2005-04-19
EP2179745A1 (en) 2010-04-28
HK1075208A1 (en) 2005-12-09
EP1515750B1 (en) 2010-08-11
US20110033458A1 (en) 2011-02-10
NO20050096L (no) 2005-02-04
PL372070A1 (en) 2005-07-11
AU2003242646A1 (en) 2003-12-22
SG162616A1 (en) 2010-07-29
CN1658904A (zh) 2005-08-24
ZA200409137B (en) 2005-08-31
JP2005535608A (ja) 2005-11-24
ATE476995T1 (de) 2010-08-15
US20050271669A1 (en) 2005-12-08
IL165180A0 (en) 2005-12-18
CA2487147A1 (en) 2003-12-18
WO2003103712A1 (en) 2003-12-18
EP1515750A1 (en) 2005-03-23
CN101816792A (zh) 2010-09-01
DE60333754D1 (de) 2010-09-23

Similar Documents

Publication Publication Date Title
BR0311714A (pt) Combinações que compreendem epotilonas e seus usos farmacêuticos
WO2006059234A3 (en) Bicyclic amides as kinase inhibitors
BRPI0508540B8 (pt) composto, composição farmacêutica, e, uso de um composto
EA200501849A1 (ru) Производные пиразолохиназолина: способ получения и применение в качестве ингибиторов киназ
EA200401019A1 (ru) Дозированная лекарственная форма для перорального применения, содержащая ингибитор pde 4 в качестве действующего вещества и поливинилпирролидон в качестве вспомогательного вещества
PA8606201A1 (es) DERIVADOS DE PIRROLO[3,4-c) PIRAZOL ACTIVOS COMO INHIBIDORES DE QUINASA, PROCESO PARA SU PREPARACION Y COMPOSICIONES FARMACEUTICAS QUE LOS COMPRENDEN
DE60315479D1 (de) Pyrimidinamid derivate und deren verwendung
DE60134021D1 (de) Pharmazeutische zubereitungen zur angiogenese-therapie
NO20055891L (no) Kinazolinderivater som aurorakinaseinhibitorer
BR9807950A (pt) Composto, composição farmacêutica, uso de um composto, e, processos para tratar ou reduzir o risco de doenças ou condições humanas, o risco de doença inflamatória o risco da dor e para a preparação de um composto
BR0307588A (pt) Composto, inibidor de gsk-3, composição farmacêutica, e, agente terapêutico ou preventivo para uma doença
BRPI0409884A (pt) compostos, composições farmacêuticas, método para o tratamento ou porfilaxia de doenças, e, usos de compostos e de um ou mais compostos em combinação com outros compostos farmacologicamente ativos
UY29561A1 (es) Derivados de quinazolina, composiciones farmacéuticas que los contienen, procedimientos de preparación y aplicaciones
BRPI0414777A (pt) compostos, composições farmacêuticas, uso de um ou mais compostos, e, método de tratar um paciente que sofre de um distúrbio
GT200500020A (es) Derivados de 1h-tieno[2,3-c]pirazol utiles como inhibidores de quinasa.
BR0211271A (pt) Combinações compreendendo epotilonas e usos farmacêuticos das mesmas
SE0002729D0 (sv) Novel compound form
ECSP045479A (es) Combinaciones que comprenden epotilonas y sus usos farmaceuticos
BRPI0520806A2 (pt) derivados pirrólicos, processos para a preparação de compostos, seu uso e composição farmacêutica que os contém
WO2004056306A3 (de) Verwendung von l-dopa, seiner derivate und diese verbindungen enthaltender arzneimittel zur prophylaxe psychotischer erkrankungen
RU2004139234A (ru) Комбинации, включающие эпотилоны, и их фармацевтическое применение
BR0312283A (pt) Combinação compreendendo um agente de alquilação e um agente redutor da atividade de vegf
AR042210A1 (es) Composicion farmaceutica que contiene antagonistas de leucotrienos b4 (ltb4) e inhibidores de la ciclooxigenasa (cox)
UY26840A1 (es) Composición farmacéutica a base de cocaetileno y su utilización para el tratamiento de la dependencia a las sustancias psicoactivas
EA200501366A1 (ru) Лекарственное средство

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 11A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2260 DE 29/04/2014.